Correlation of TTF-1 expression with chemotherapy efficacy and prognosis in patients with advanced lung adenocarcinoma

Abstract

Objective \nTo investigate the correlation of the expression of thyroid transcription factor-1 (TTF-1) with the efficacy and prognosis of different chemotherapy regimens in patients with advanced lung adenocarcinoma. \n \n \nMethods \nA total of 98 patients with advanced lung adenocarcinoma diagnosed and treated in our hospital from April, 2015 to May, 2018 were prospectively selected. According to the random number table method, they were divided into a pemetrexed + cisplatin / carboplatin group (PEM + DDP/CBP, 46 cases) and a pemetrexed + nedaplatin group (PEM + NDP, 52 cases). The expression of TTF-1 was detected by immunohistochemistry. The relationship between TTF-1 and objective response rate (ORR) as well as disease control rate (DCR) was observed. The correlation between TTF-1 expression and prognosis survival was analyzed by Kaplan-Meier survival curve. \n \n \nResults \nThere were no statistical differences in ORR and DCR between the two groups (both P>0.05). But the ORR and DCR of the TTF-1-positive patients in the PEM+NDP group were higher than those of the TTF-1-negative patients (both P 0.05). The median PFS and OS of the patients with TTF-1 positive expression in the PEM + NDP group were longer than those of the TTF-1 negative patients (14 months vs. 8 months and 17 months vs. 12 months; both P 0.05). \n \n \nConclusion \nThe positive expression of TTF-1 in patients with advanced lung adenocarcinoma may predict the better curative effect and survival prognosis of PEM+ NDP chemotherapy. \n \n \nKey words: \nLung adenocarcinoma;\xa0Advanced;\xa0Thyroid transcription factor 1;\xa0Chemotherapy;\xa0Prognosis